Articles
POSER OVER MEDICINE SUPPLIES
(Martin Khor,9-Jan-2012,The Star (Malaysia) )
Patients worldwide suffering from various ailments have benefited from cheap generic Indian drugs.
Acknowledgment - Thanks to Mr. Gopa Kumar of Third World Network for drawing attention to this case More...
MNC patent monopoly and takeover of generics in India
(K. M. Gopakumar,21-Dec-2011,SUNS and TWN )
A new study reveals that multinational pharmaceutical companies are exploiting their product monopoly to charge high prices under Indias product patent law as well as gradually taking over the domestic generic sector. More...
AIA Ho! - US Patents Act Amendments
(Dr Gopakumar G Nair,5-Oct-2011,Pharmabiz)
Something long overdue in the patent regime of the USA the America Invents Act has been passed by the US Congress amending the 35USC American Patents Act and Procedures thereof. More...
Bionic Bacteria May Help Make New Drugs, Biofuels: Artificially Enhanced Bacteria Capable of Producing New Kinds of Synthetic Chemicals
(Science News,22-Sep-2011,ScienceDaily )
For the first time the scientists were able to create bacteria capable of effectively incorporating unnatural amino acids artificial additions to the 20 naturally occurring amino acids used as biological building blocks into proteins at multiple sites. More...
New drug discovery - need for introspection!
(Dr. Gopakumar G. Nair ,15-Jun-2011,Pharmabiz)
Trend of annual NCE approvals have been alarmingly coming down from average of about 50 prior to the nineties to almost an average of below 30 in the recent times. More...
India asks firms to provide data on working of patents
(By Anju Ghangurde,20-Jan-2010,Scrip World Pharmaceutical News)
India has asked all patentees and licensees to provide information on the working of patents in the country before March 31st 2010. More...
People who will save the world
(Yusuf K. Hamied ,8-Jan-2010,FORBES INDIA)
For someone who calls himself a man of science Yusuf K. Hamied has a patent dis like for intellectual property rights. More...
Genesis of Pregrant Oppositions & its current status
(Dr Gopakumar G Nair,10-Dec-2009,Pharmabiz)
The Patents Act 1970 as amended in 2005 with active participation from the lawmakers in the floor of the House introduced the provision for Pregrant Opposition for the first time in India. More...
Blocked in transit
(Dr Gopakumar Nair ,D G Shah,30-Nov-2009,Express Pharma)
As per TRIPS provision under Section 255 cross border measures really do not include patents and in transit materials because a majority of issues of counterfeit are related to quality and misbranding wrong branding informs Dr Gopakumar Nair Patent Attorney and CEO Gopakumar Nair Associates. More...
THE COMERCIAL CHAMBER OF JUSTICE DECLARED THE NULLITY OF THE TRADEMARK FEDERAL EXPRESS - CLASS 38.
(Claudio Marcelo Albarellos,4-Oct-2009,ALBARELLOS | ASOCIADOS)
The National Federal Court of Appeals issued a very interesting sentence in which develops very important concepts as the trademark the registration and their reaches among many others. More...
Latest Situations and Developments of Trademark Applications and Examinations in China
(Mr Hung-Pang Bian ,21-Aug-2009,World Patent & Trademark Law Office)
According to a recent mass media report Fu Shuangjian who is currently deputy chief of Administration Bureau of Chinese Industry and Commerce paid a visit to Taiwan on June 15 2009 during which he gave a comprehensive presentation and outline on the latest situations and developments of Trademark applications and examinations in China. More...
Mr D G Shah presentation to Secretary, DoP
(21-Jul-2009,IDMA)
Reproduced with due permission from Mr. D G Shah and IDMA. More...
Ready for Round 2
(Dr Gopakumar G Nair,Dr M Venkateswarlu,Tapan Ray,A S Krishna,Ranga Iyer,A S Krishna,16-May-2009,Express Pharma)
Legally speaking a patent is an exclusionary right given by the government or the authorised authority to its inventor for a particular duration in respect of his invention. More...
Blocked in transit
(D G Shah,Dr. Gopakumar Nair,10-Apr-2009,Express Pharma)
As aggressive IP enforcement continues at the hands of EU ports should goods in transit be protected when they are without a doubt intended for markets where their use is legitimate. More...
Form No. 44 Entry relating to Patent Status is redundant and unnecessary
(Shri Dedashish Panda ,07-Apr-2009,IDMA BULLETIN)
In the recent controversy on Marketing Approval the entry Patent Status in Form No. 44 came up for discussion rather prominently. More...
More than just a rubber stamp?
(Dr Gopakumar G Nair,Dr Ajit Dangi,Dr Venkateswarlu,15-Mar-2009,Express Pharma)
It is unfair to blame the MNCs for everything. The MNCs themselves are the most frequent targets of USFDA. More...
A tug of war
(Dr Gopakumar Nair, Dilip G Shah, Tapan Ray, Dr Ajit Dangi, Priyank Gupta,28-May-2008,Express Pharma)
India's nasacent patent regime is under the scanner and the industry is grappling with questions like - What is the long term solution to balance patent protection with patient needs, in developing countries like India and especially with life threatening conditions like India and especially with life threatening conditions like cancer and AIDS? What is the situation in other countries on such issues? More...
Why is the DCGI trying to implement a 'patent-registeration' linkage system in India?
(Prashant Reddy,09-May-2008,Spicy IP)
The Drug Controller General of India - Dr. Surinder Singh - has made a public statement that he intends to link up regulatory approval for drugs to the patenting system i.e. he has gone on to record to state that the DCGI will not grant regulatory approval for generic drugs if in case the innovator drug still has a valid patent covering it. More...
IP education -The Indian reality
(Dr Gopakumar G. Nair,Chronicle,13-Dec-2007,PharmaBiz)
The emergence of intellectual property (IP) through WTO & TRIPs to the forefront of international trade had taken India by surprise in the early 90's. More...
Opposing before granting
(Ashwini Sandu & Raju Kumar,Chronicle,13-Dec-2007,PharmaBiz)
The emergence of Pre-grant opposition is a newly emerging hot topic of discussion on the international scenario too. More...
Notices regarding Claims And Continuations Rules
(5-Nov-2007,USPTO)
Recent USPTO Announcement of postponing the implementation of proposed revision in the rules of practice in USPTO.The report is reproduced . More...
Ranbaxy gets favourable decision from German court against Pfizer
(Our Bureau, Mumbai,31-Oct-2007,PharmaBiz)
Ranbaxy Laboratories Limited (RLL) has announced that the Federal Patent Court of Germany located in Munich, handed down a favourable decision for Ranbaxy in its case against (Pfizer) Warner-Lambert's European Patent 409 281 (281) More...
USPTO Publishes Examination Guidelines for Determining Obviousness in Light of the Supreme Court's KSR v Teleflex Decision
(10-Oct-2007,USPTO)
The Department of Commerce's United States Patent and Trademark Office (USPTO) has published Examination Guidelines (Guidelines) to help USPTO examiners make appropriate decisions regarding the obviousness of claimed inventions in light of the Supreme Court's decision in KSR International Co. v. Teleflex Inc., 550 U.S., 82 USPQ2d 1385 (2007) (KSR). More...
The Examination Guidelines can be found at
More...
Patenting: The Indian way
(27-Sep-2007,PharmaBiz)
India's entry into the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) compliant product patent regime has stirred hornet's nest in the global IP scenario. More...
For a fool proof patent
(22-Sep-2007,Express Pharma)
Pharma companies employ various strategies while drafting patent claims. More...
USPTO Publishes Measures to Improve Patent Quality
(20-Aug-2007,USPTO)
USPTO moving forward to improve patent quality -Federal Register publishes new draft rules will become effective 1st November 2007.For details go to More...
Verdict On Glivec
(9-Aug-2007,CHRONICLE PHARMABIZ)
The controversial patent litigation over Glivec has come to almost to an end on last Monday with the Madras High Court rejecting Novartis' petition challenging More...
Indian Pharma Industry: The Road Ahead
(Feb-Mar-2007,Modern Pharmaceuticals)
In this article, Dr. Nair takes a look at the Indian Pharma Industry and the future trends in the industry. More...
Time to "bridge the gulf"
(25-Jan-2007,PharmaBiz)
In this article, Dr. Nair takes a look at the potential for growth for the Indian Pharma sector in the Gulf countries. More...
The Mashelkar Committee Report.
More...
Invitation from the Department of Science and Technology for Research Proposals
Invitation from the Department of Science and Technology for Research Proposals from Academic Institutions/National Laboratories and Industries in Drugs and Pharma Sector under the Drugs and Pharmaceutical Research Programme (DPRP). More...
Indian Patent Act and its impact on Pharma Industry.
(2006,Pharmexcil)
In this article, Dr. Nair takes an in-depth look at the Indian Patent Act and its impact on the Indian Pharma Industry. More...
Incremental innovations in drug research
(30-Nov-2006,PharmaBiz)
This article takes a look at the rising importance of "Incremental Innovations" for pharma companies and also takes a look at the Indian scenario for the same. More...
People Assets - Are we on track.
(1-Nov-2006,Express Pharma)
In this article, Dr. Gopakumar Nair opines that a road block to the Indian pharma success story could be diminishing human resources. More...
Towards greater IPR protection
(19-Oct-2006,PharmaBiz)
This article takes a look at the current IPR scenario in the Middle East countries, giving UAE as a specific example. More...
Data exclusivity - a practical model for India
(28-Sep-2006,PharmaBiz)
This article gives the significance of data exclusivity for the Indian pharma industry and a practical model for implementing the same. More...
TRIPs & Patents
(Aug-2006,Modern Pharmaceuticals)
This is the first draft of the article which appeared in Modern Pharmaceuticals, August-September 2006 and describes the impact of TRIPS on the Indian Pharmaceutical industry. More...
The decision of the Indian Patent Office
The decision of the Indian Patent Office (IPO) regarding the opposition filed by M/s Cipla Ltd to the patent application no. 1602/MAS/1998 filed by M/s Novartis AG for Gleevec (Imatinib Mesylate). More...
IP Protection post-2004: A Review
(1-Dec-2005,PharmaBiz)
This article gives the scenario of IP protection in India, after 2004. More...
Is latest US Appeal Court's En Banc judgment anti-"evergreening"?
(22-Oct-2005)
This article takes a look at the anti-evergreening steps taken by the Indian Parliament and a case study regarding a recent US judgment concerned with evergreening. More...
Harmonised Patent Law installed at WIPO
(23-Jun-2005,PharmaBiz)
This article gives an overview of the problems faced by SPLT (Substantive Patent Law Treaty) at the June meeting of the SCP (Standing Committee on the Law of Patents). More...
Additional features of the new Patent Ordinance
(15-Jan-2005,PharmaBiz)
This article draws attention to certain aspects of the new patent amendment that needs closer attention. More...
Option in Transition - Patent Ordinance - 2004
(29-Dec-2004,PharmaBiz)
This article states the new features of the new ordinance issued by the Government of India. More...
Ordinance 2004 (Patent tsunami or parting gift)
(29-Dec-2004,Pharma Pulse)
This article mentions a few salient features of the 2004 Ordinance to the Patent Act, 1970. More...
Product patents and transition status
(23-Dec-2004,PharmaBiz)
This article discusses the 3rd Amendment to The Patent Act, 1970. More...
Discovery of India The El-"CRO"rado (CRO - Contract Research Organisations)
(28-Jun-2004,Pharma Pulse)
This article cries out for a re-discovery of India for its technological treasures. More...
Patents and Trade Secrets - "Eat your cake and keep it too"
(31-May-2004,PharmaBiz)
This article takes a look at the problem of "perennial patenting" with regards to micro-organisms. More...
Emergency Encounter and other Reminiscences
(31-May-2004,Pharma Pulse)
This article takes a look at a few meetings Dr. Gopakumar Nair attended in Delhi, during the Emergency. More...
Drug Controller From Industry
(9-Feb-2004,Pharma Pulse)
This article states that the Drug Controller should be a person from the Industry and the advantages of the same. More...
IP in India: A Hobson's Choice
(25-Dec-2003,PharmaBiz)
This article discusses the limited options facing India regarding IP. More...
Agriculture: Great Expectations from Cancun? for the day after syndrome
(3-Sep-2003,PharmaBiz)
This article discusses the problems faced on the road from Doha to Cancun. More...
Patent Rules 2003 Ushers in the Patent (Amendment) Act, 2002
(9-July-2003,PharmaBiz)
This article discusses the changes brought about by the Patent (Amendment) Act, 2002. More...
Balancing benefits and downsides of Intellectual Property
(18-Jun-2003,PharmaBiz)
This article discusses the balancing act to be performed by various countries with regards to IP. More...
Indian Patent Law and Pharma Industry
(29-May-2003,PharmaBiz)
This article discusses the Indian Patent Law w.r.t. the Pharma Industry. More...
Critical commentary on changes in Patent Law effective 20th May 2003
(23-May-2003)
This article is a critical commentary on the changes in the Patent Law. More...
Hathi mere Sathi
(17-May-2003,Pharma Pulse)
This article starting with an anecdote, takes a brief look at the Hathi Commission Report. More...
Pharma Technology Upgradation
(30-Jan-2003)
This article states the need for technology upgradation in the Indian Pharma sector. More...
A problem of mindset
(23-July-2002,PharmaBiz)
This article details the changes in mindset that have to be made in the Indian Pharma industry to meet the strong global demand. More...
Indian Pharmaceutical Industry - Some myths and few facts
(29-May-2002,Pharmabiz)
This article states some myths and a few facts regarding the Indian Pharmaceutical Industry. More...
An ode to the budget (& the FM)
(29-Jan-2002,PharmaBiz)
This article, in the form of an ode, requests the FM to do away with regulatory pricing in the Pharma industry. More...
Point-Counterpoint: Doha Ministerial meet
(11-Dec-2001,PharmaBiz)
This article discusses the Doha Ministerial meet. More...
.
.